US Edition
Panavance Therapeutics Reports Promising Phase 1 Results for Pancreatic Cancer Therapy
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Panavance Therapeutics Reports Promising Phase 1 Results for Pancreatic Cancer Therapy
BERWYN, PA — Panavance Therapeutics Inc. has shared promising interim findings from its ongoing Phase 1 clinical trial investigating misetionamide (GP-2250), a novel second-line therapy for advanced pancreatic cancer. These results, presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, demonstrate encouraging safety and efficacy for the combination of misetionamide and gemcitabine. To date, the dose escalation trial …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
